Zynerba Pharmaceuticals Inc.

Zynerba Pharmaceuticals Inc.

At Zynerba Pharmaceuticals, our team is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for patients affected by rare and near-rare neuropsychiatric conditions. Often, these diseases have few, if any, treatment options and can leave patients and their families feeling helpless and alone. Zynerba is committed to developing breakthrough therapies to transform the quality of lives of patients and their families as they battle these conditions.
Medical Resources
1d 5d 1m 6m 1y Max

Zynerba Pharmaceuticals Inc. News

20 Jun

Fed Statement Keeps Rally Alive

Fed Statement Keeps Rally Alive

19 Jun

Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know

Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $13.91, moving +0.87% from the previous trading session.

13 Jun

MediaJel Acquires Potnt Agency, Adds Merida Capital's Thomas Harrison As Chairman

The company appointed Thomas Harrison, Senior Operating Partner at Merida Capital Partners, as Chairman of the Board. Before joining the company, Harrison was Chairman Emeritus of Omnicom Group Inc (NYSE:...

11 Jun

Why Zynerba Pharmaceuticals Stock Is Skyrocketing Today

A new patent is generating excitement among investors for this clinical-stage biotech stock.

11 Jun

Zynerba Pharmaceuticals Rises Due to Patent News

Zynerba Pharmaceuticals Rises Due to Patent NewsZynerba PharmaceuticalsZynerba Pharmaceuticals (ZYNE) has risen 18.6% as of 10:40 AM EST on June 11. The stock has been among the top-performing stocks this...

11 Jun

Healthcare tops midday movers

Gainers: Jaguar Health (NASDAQ: JAGX ) +60% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +40% . TORM (NASDAQ: TRMD ) +20% . Rekor Systems, Inc. (REKR) +17% . Enzo Biochem, Inc. (NYSE: ENZ ) +17% ....

11 Jun

Zynerba Advances Cannabidiol Treatment With New Patent Win

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a company that focuses on treating rare and near-rare neuropsychiatric disorders through cannabinoid therapies, said Tuesday it received a new U.S. patent for...

11 Jun

Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Cannabidiol

Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S....

11 Jun

Zynerba nabs new patent in U.S.; shares up 5% premarket

The USPTO has issued Zynerba Pharmaceuticals (NASDAQ: ZYNE ), Patent No. 10,314,792, titled Treatment of Autism Spectrum Disorder with Cannabidiol which includes claims directed to methods of treating...

10 Jun

Zynerba Pharmaceuticals: An Updated Investment Thesis

If two men on the same job agree all the time, then one is useless. If they disagree all the time, both are useless . Darryl F. Zanuck Few stocks have been as volatile recently as Zynerba Pharmaceuticals...

Load more

About Zynerba Pharmaceuticals Inc.

Zynerba’s mission is to develop next-generation transdermally-delivered cannabinoid therapeutics to help address significant unmet medical needs and improve the lives of patients with rare and near-rare neuropsychiatric conditions such as Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), 22q, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).

Our goal is to advance the science of therapeutic cannabinoids, and to improve the lives of patients battling severe neuropsychiatric conditions including Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), 22q, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).

Our approach is to utilize our pharmaceutically-manufactured, penetration-enhanced transdermal cannabinoid product candidate to modulate pathways in the central nervous system that, when disrupted, cause certain neurological diseases. By doing so, we hope to provide new treatment options for patients battling certain rare neuropsychiatric diseases.


Armando Anido
Chairman of the Board and Chief Executive Officer
Terri B. Sebree
Jim Fickenscher
Chief Financial Officer, Vice President, Corporate...
Joe Apostolico
Vice President, Human Resources
Donna L. Gutterman
Vice President, Medical
Suzanne M. Hanlon
Vice President and General Counsel
Terry Hurst
General Manager, Zynerba Pharmaceuticals Pty Ltd (...
Ray Mannion
Vice President, Manufacturing
Carol O’Neill
Vice President, Development
Will Roberts
Vice President, Investor Relations and Corporate C...
Brian Rosenberger
Vice President, Commercial and Business Developmen...
Nancy Tich
Vice President, Clinical
Warren D. Cooper
Lead Independent Director
William J. Federici
Chair, Audit Committee
Thomas L. Harrison
Chair, Nominations and Corporate Governance Commit...
Daniel L. Kisner
Chair, Compensation Committee
Kenneth I. Moch
Member, Audit Committee

Participation in events

$ 0.35
Market cap:
274.607 M